基础医学与临床 ›› 2017, Vol. 37 ›› Issue (5): 696-704.

• 研究论文 • 上一篇    下一篇

TRPC1/ORAI1 复合体调节HUVEC SOC和ROC介导的Ca2+内流和NO生成

王腊梅1,胡清华2,钟华1,唐娜3,孙志萍2,何芳2   

  1. 1. 石河子大学医学院病理生理学教研室
    2. 石河子大学医学院
    3. 新疆石河子大学医学院
  • 收稿日期:2015-11-19 修回日期:2016-07-07 出版日期:2017-05-05 发布日期:2017-04-19
  • 通讯作者: 何芳 E-mail:FangF2002shz@126.com
  • 基金资助:
    TRPCs, STIMs及Orais在钙敏感受体介导钙内流及一氧化氮生成中作用和机制研究

TRPC1/ORAI1 requlates Ca2+ entry and NO generation mediated by HUVEC SOC and ROC

  • Received:2015-11-19 Revised:2016-07-07 Online:2017-05-05 Published:2017-04-19
  • Contact: Fang HE E-mail:FangF2002shz@126.com

摘要: 目的 研究瞬时受体电位通道1(TRPC1)/钙释放激活钙通道调节分子1(ORAI1)复合体在人脐静脉内皮细胞(HUVEC) 钙池操纵性钙通道(SOC) 和受体操纵性钙通道(ROC)介导Ca2+内流和NO生成中的作用。方法 取2~3代HUVECs,将构建的TRPC1和ORAI1干扰质粒分别转染入HUVEC。用激光共聚焦显微镜观察细胞转染效果,real-time PCR和Western blotting检测TRPC1、ORAI1 mRNA和蛋白的表达及抑制效率。细胞随机分组:特异性质粒转染组即实验组,未转染组即空白对照组及空质粒组(vehicle组),将上述3组细胞分别与CaR激动剂、ROC模拟剂(12-o-十四烷酰佛波醋酸酯-13)TPA+CaR负性变构调节剂Calhex231、蛋白激酶C(PKC)抑制剂Ro31-8220、经典型PKCs和PKCμ抑制剂Go6967孵育,用荧光探针Fura-2/AM及DAF-FM负载方法同步检测[Ca2+]i和NO。随后将构建的TRPC1和ORAI1干扰质粒同时转染入HUVEC,与CaR激动剂孵育后检测[Ca2+]i和NO,用免疫共沉淀法检测TRPC1和ORAI1的相互作用。结果:1) 与对照组相比,TRPC1及ORAI1组,mRNA和蛋白表达均明显降低(p<0.05); 2) 在4种不同处理作用下,TRPC1及ORAI1转染组中[Ca2+]i△ratio值和NO净荧光强度值均明显降低(p<0.05);3) 与对照组及单转染TRPC1及ORAI1组比,共转染组[Ca2+]i△ratio值和NO净荧光强度值均明显降低(p<0.05);4) TRPC1与ORAI1相互作用形成复合体,且在CaR激动剂的剌激下相互作用增强。结论 TRPC1与ORAI1复合体共同调节CaR经SOC和ROC激活介导的Ca2+内流和NO生成。

关键词: TRPC1, Orai1, 一氧化氮, 钙离子, 人脐静脉内皮细胞

Abstract: Objective To study the function of TRPC1/ORAI1 in store and receptor-operated Ca2+ entry and nitric oxide generation by SOC and ROC in human umbilical vein endothelial cells. Methods HUVECs were collected and cultured to the second~third passage. We silenced the expression of their genes in HUVEC by transfection constructed TRPC1 or ORAI1 RNA interference plasmids. The interference efficiency of their protein and mRNA levels were determined by Western blotting and real-time PCR, respectively. The cells were divided into: short hairpin RNA(shRNA) group; control group and vehicle group. The cells were incubated with CaR agonist, CaR negative allosteric modulator Calhex231 and receptor-operated channels (ROC) analogue TPA, Protein kinase C (PKC) inhibitor Ro31-8220, PKCs and PKCμ inhibitor Go6967 incubate, intracellular Ca2+ concentration ([Ca2+]i) was detected using the fluorescence Ca2+ indicator Fura-2/AM, the production of NO was determined by DAF-FM of every group in HUVEC. HUVECs were transduced with shRNA-TRPC1 and shRNA-ORAI1 at same time, after cultured with CaR agonist, [Ca2+]i and the production of NO was determined. The interaction between ORAI1 and TRPC1 were examined by Co-immunoprecipitation. Results 1) Compared with control group, shRNA targeted to the TRPC1 or ORAI1 genes decreased their mRNA and protein levels, respectively (p<0.05); 2) In four different treatment under the action of factors, the [Ca2+]i and the net NO fluorescence intensity ratio values of transfection of TRPC1 or ORAI1 shRNA group were significantly reduced (p<0.05). 3) Compared with the control and single shRNA group, the[Ca2+]i and the net NO fluorescence intensity ratio values of transfection of TRPC1 and ORAI1 shRNA group were significantly reduced (p<0.05). 4) ORAI1 co-precipitates with TRPC1, indicating internation of a molecular complex had enhanced by CaR agonist. Conclusions TRPC1, ORAI1 are components of SOCE and ROCE channels in store and receptor-operated Ca2+ entry and nitric oxide generation in human umbilical vein endothelial cells.

Key words: TRPC1, ORAI1, Nitric Oxide, Ca2+, Human umbilical vein endothelial cells